Renaissance Technologies
IKT icon

Renaissance Technologies’s Inhibikase Therapeutics IKT Stock Holding History

Renaissance Technologies’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$27.7K Buy
+16,500
New +$29.3K ﹤0.01% 3153
2024
Q4 		– Sell
-19,922
Closed -$25.9K – 3725
2024
Q3 		$25.9K Sell
19,922
-900
-4% -$1.21K ﹤0.01% 3414
2024
Q2 		$25.2K Sell
20,822
-600
-3% -$1.03K ﹤0.01% 3362
2024
Q1 		$46K Sell
21,422
-3,000
-12% -$6.62K ﹤0.01% 3496
2023
Q4 		$31K Buy
24,422
+8,300
+51% +$8.59K ﹤0.01% 3526
2023
Q3 		$22K Buy
16,122
+3,400
+27% +$7.62K ﹤0.01% 3515
2023
Q2 		$46K Buy
12,722
+1,505
+13% +$5.61K ﹤0.01% 3631
2023
Q1 		$44K Buy
11,217
+2,550
+29% +$10.6K ﹤0.01% 3687
2022
Q4 		$26K Sell
8,667
-12,114
-58% -$48K ﹤0.01% 3914
2022
Q3 		$113K Sell
20,781
-16,202
-44% -$85.3K ﹤0.01% 3552
2022
Q2 		$165K Buy
36,983
+5,571
+18% +$32.9K ﹤0.01% 3717
2022
Q1 		$279K Sell
31,412
-2,121
-6% -$17.1K ﹤0.01% 3501
2021
Q4 		$296K Buy
+33,533
New +$370K ﹤0.01% 3348

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies's IKT Position: Q1 2026 in Review

Renaissance Technologies opened a new position in Inhibikase Therapeutics (IKT) in Q1 2026: 16,500 shares worth $27.7K. The stake represents ﹤0.01% of the portfolio and ranks #3153 among its holdings. This is a return to the name: Renaissance Technologies previously reported a position in IKT as recently as Q3 2024.

Renaissance Technologies first reported a position in IKT in Q4 2021 and has held it in 13 quarters since. The position peaked at $296K in Q4 2021. 104 funds tracked by Wall St. Rank hold IKT as of Q1 2026.

  • Renaissance Technologies held 16,500 shares of Inhibikase Therapeutics worth $27.7K as of Q1 2026.
  • Inhibikase Therapeutics was a new Renaissance Technologies position in Q1 2026.
  • Inhibikase Therapeutics made up ﹤0.01% of Renaissance Technologies's portfolio in Q1 2026, its #3153 holding.
  • Renaissance Technologies first reported a position in Inhibikase Therapeutics in Q4 2021 and has held it in 13 quarters since.
  • Renaissance Technologies's Inhibikase Therapeutics position peaked at $296K in Q4 2021.
  • 104 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.